Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: An in vivo electrophysiologic characterization

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 3, 2014, Pages 585-595

  Oosterhof, Chris A ^a,b   El Mansari, Mostafa ^a   Blier, Pierre ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE METHYL ESTER; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; APOMORPHINE; ARIPIPRAZOLE; BREXPIPRAZOLE; CLONIDINE; DOPAMINE; DOPAMINE 2 RECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NORADRENALIN; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; 7-(4-(4-(1-BENZOTHIOPHEN-4-YL)PIPERAZIN-1-YL)BUTOXY)QUINOLIN-2(1H)-ONE; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; HIPPOCAMPUS; IN VIVO STUDY; LOCUS CERULEUS; LOW DRUG DOSE; MALE; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROTRANSMISSION; NONHUMAN; PYRAMIDAL NERVE CELL; RAT; VENTRAL TEGMENTUM; ANIMAL; DRUG EFFECTS; ELECTROPHYSIOLOGY; NERVE CELL; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME;

ACTION POTENTIALS; ANIMALS; DOPAMINE; ELECTROPHYSIOLOGICAL PHENOMENA; MALE; NEURONS; NOREPINEPHRINE; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; THIOPHENES; TIME FACTORS;

EID: 84908428543     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.218578     Document Type: Article

References (59)

1. Arborelius L, Chergui K, Murase S, Nomikos GG, Höök BB, Chouvet G, Hacksell U, and Svensson TH (1993) The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol 347:353-362.
2. Arnsten AF (2004) Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology (Berl) 174:25-31.
3. Blier P and El Mansari M (2013) Serotonin and beyond: therapeutics for major depression. Philos Trans R Soc Lond B Biol Sci 368:20120536.
4. Blier P, Ramdine R, Galzin AM, and Langer SZ (1989) Frequency-dependence of serotonin autoreceptor but not alpha 2-adrenoceptor inhibition of [3H]-serotonin release in rat hypothalamic slices. Naunyn Schmiedebergs Arch Pharmacol 339:60-64.
5. Blier P and Szabo ST (2005) Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 66 (Suppl 8):30-40.
6. Blier P and Ward NM (2003) Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 53:193-203.
7. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, and Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389.
8. Chaput Y, Blier P, and de Montigny C (1986) In vivo electrophysiological evidence for the regulatory role of autoreceptors on serotonergic terminals. J Neurosci 6:2796-2801.
9. Chernoloz O, El Mansari M, and Blier P (2009) Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. Psychopharmacology (Berl) 206:335-344.
10. Chernoloz O, El Mansari M, and Blier P (2012) Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission. Neuropsychopharmacology 37:1717-1728.
11. Curet O and De Montigny C (1988) Electrophysiological characterization of adrenoceptors in the rat dorsal hippocampus. I. Receptors mediating the effect of microiontophoretically applied norepinephrine. Brain Res 475:35-46.
12. Dahan L, Husum H, Mnie-Filali O, Arnt J, Hertel P, and Haddjeri N (2009) Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. J Psychopharmacol 23:177-189.
13. Day HE, Campeau S, Watson SJ, Jr, and Akil H (1997) Distribution of α 1a-, α 1b- and α 1d-adrenergic receptor mRNA in the rat brain and spinal cord. J Chem Neuroanat 13:115-139.
14. De Montigny C, Wang RY, Reader TA, and Aghajanian GK (1980) Monoaminergic denervation of the rat hippocampus: microiontophoretic studies on pre- and postsynaptic supersensitivity to norepinephrine and serotonin. Brain Res 200:363-376.
15. Díaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, and Artigas F (2005) Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 25:10831-10843.
16. Dong J, De Montigny C, and Blier P (1998) Full agonistic properties of BAY x 3702 on presynaptic and postsynaptic 5-HT1A receptors electrophysiological studies in the rat hippocampus and dorsal raphe. J Pharmacol Exp Ther 286:1239-1247.
17. Dremencov E, El Mansari M, and Blier P (2007) Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry 61:671-678.
18. El Mansari M, Sánchez C, Chouvet G, Renaud B, and Haddjeri N (2005) Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology 30:1269-1277.
19. Fawcett J and Barkin RL (1998) Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 51:267-285.
20. Ghanbari R, El Mansari M, and Blier P (2010) Sustained administration of trazodone enhances serotonergic neurotransmission: in vivo electrophysiological study in the rat brain. J Pharmacol Exp Ther 335:197-206.
21. Ghanbari R, El Mansari M, and Blier P (2011) Enhancement of serotonergic and noradrenergic neurotransmission in the rat hippocampus by sustained administration of bupropion. Psychopharmacology (Berl) 217:61-73.
22. Ghanbari R, El Mansari M, Shahid M, and Blier P (2009) Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain. Eur Neuropsychopharmacol 19:177-187.
23. Glazer WM(2000) Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 61 (Suppl 3):16-21.
24. Grace AA and Bunney BS (1983) Intracellular and extracellular electrophysiology of nigral dopaminergic neurons - 1. Identification and characterization. Neuroscience 10:301-315.
25. Grace AA and Bunney BS (1984) The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 4:2877-2890.
26. Gronier B (2008) Involvement of glutamate neurotransmission and N-methyl-daspartate receptor in the activation of midbrain dopamine neurons by 5-HT1A receptor agonists: an electrophysiological study in the rat. Neuroscience 156:995-1004.
27. Haddjeri N, Blier P, and de Montigny C (1996) Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther 277:861-871.
28. Haddjeri N, Blier P, and de Montigny C (1998) Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission. J Affect Disord 51:255-266.
29. Hadrava V, Blier P, and de Montigny C (1996) Partial agonistic activity of R- and S-enantiomers of 8-OH-DPAT at 5-HT1A receptors. J Psychiatry Neurosci 21:101-108.
30. Hadrava V, Blier P, Dennis T, Ortemann C, and de Montigny C (1995) Characterization of 5-hydroxytryptamine1A properties of flesinoxan: in vivo electrophysiology and hypothermia study. Neuropharmacology 34:1311-1326.
31. Hand TH, Hu X-T, and Wang RY (1987) Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons. Brain Res 415:257-269.
32. Hirose T, Maeda K, Stensbøl TB, and Kikuchi T (2014) Synergistic effects of brexpiprazole with SSRI/SNRI/diazepam on forced swim test and marble burying behavior in mice. Biol Psychiatry 75 (Suppl 9):132S.
33. Kapur S, Zipursky R, Jones C, Remington G, and Houle S (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520.
34. Kuroki T, Nagao N, and Nakahara T (2008) Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res 172:199-212.
35. Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade RD, Stensbøl TB, Bundgaard C, Arnt J, and Kikuchi T (2014a) Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 350:605-614.
36. Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, and Mørk A, et al. (2014b) Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 350:589-604.
37. Marcus MM, Wiker C, Fra˚nberg O, Konradsson-Geuken A, Langlois X, Jardemark K, and Svensson TH (2010) Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. Int J Neuropsychopharmacol 13:891-903 Cambridge University Press.
38. Menkes DB, Baraban JM, and Aghajanian GK (1981) Prazosin selectively antagonizes neuronal responses mediated by alpha1-adrenoceptors in brain. Naunyn Schmiedebergs Arch Pharmacol 317:273-275.
39. Mongeau R, Blier P, and de Montigny C (1993) In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of alpha 2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 347:266-272.
40. Mongeau R, de Montigny C, and Blier P (1994) Electrophysiologic evidence for desensitization of alpha 2-adrenoceptors on serotonin terminals following long-term treatment with drugs increasing norepinephrine synaptic concentration. Neuropsychopharmacology 10:41-51.
41. Nelson JC and Papakostas GI (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166:980-991.
42. Newman-Tancredi A (2010) The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs 11:802-812.
43. Piñeyro G, Blier P, Dennis T, and de Montigny C (1994) Desensitization of the neuronal 5-HT carrier following its long-term blockade. J Neurosci 14:3036-3047.
44. Pucak ML and Grace AA (1994) Evidence that systemically administered dopamine antagonists activate dopamine neuron firing primarily by blockade of somatodendritic autoreceptors. J Pharmacol Exp Ther 271:1181-1192.
45. Ranck JB, Jr (1973) Studies on single neurons in dorsal hippocampal formation and septum in unrestrained rats. I. Behavioral correlates and firing repertoires. Exp Neurol 41:461-531.
46. Rao NP and Remington G (2013) Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials. Expert Opin Investig Drugs 22:881-894.
47. Rogawski MA and Aghajanian GK (1980) Activation of lateral geniculate neurons by norepinephrine: mediation by an alpha-adrenergic receptor. Brain Res 182:345-359.
48. Rogawski MA and Aghajanian GK (1982) Activation of lateral geniculate neurons by locus coeruleus or dorsal noradrenergic bundle stimulation: selective blockade by the alpha 1-adrenoceptor antagonist prazosin. Brain Res 250:31-39.
49. Seeman P and Lee T (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217-1219.
50. Shahid M, Walker GB, Zorn SH, and Wong EHF (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23:65-73.
51. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, and Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411.
52. Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, and Kikuchi T, et al. (2007) Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl) 190:373-382.
53. Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, and Meltzer HY (1993) Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 266:1374-1384.
54. Szabo ST and Blier P (2001) Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Res 922:9-20.
55. Thase ME, Hobart M, Augustine C, Youakim JM, Zhang P, Hefting N, McQuade RD, Carson WH, Nyilas M, and Sanchez R (2014) Efficacy and safety of adjunctive brexpiprazole (OPC-34712) in major depressive disorder (MDD): a phase 3, randomized, placebo-controlled study. 22nd European Congress of Psychiatry; 2014 March 1-4; Munich, Germany. European Psychiatric Association, Strasbourg, France.
56. Vandermaelen CP and Aghajanian GK (1983) Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. Brain Res 289:109-119.
57. Wang RY (1981) Dopaminergic neurons in the rat ventral tegmental area. I. Identification and characterization. Brain Res Rev 3:123-140.
58. Wetzel JM, Miao SW, Forray C, Borden LA, Branchek TA, and Gluchowski C (1995) Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. J Med Chem 38:1579-1581.
59. Yoshimi N, Fujita Y, Ohgi Y, Futamura T, Kikuchi T, and Hashimoto K (2014) Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: A role for serotonin 5-HT1A receptors. Pharmacol Biochem Behav 124:245-249.